Core Laboratories Inc. logo

Core Laboratories Inc. (CLB)

Market Closed
17 Jul, 20:00
NYSE NYSE
$
11. 34
-0.15
-1.3055%
$
523.66M Market Cap
34.08 P/E Ratio
0.04% Div Yield
579,400 Volume
0.87 Eps
$ 11.49
Previous Close
Add Transaction
Day Range
11.18 11.52
Year Range
9.72 20.36
Want to track CLB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Core Lab Stock Plunges 18% in 3 Months: Time to Hold or Fold?

Core Lab Stock Plunges 18% in 3 Months: Time to Hold or Fold?

CLB faces persistent geopolitical uncertainty, weaker laboratory activity, cost inflation and delayed shipments, limiting visibility into a stronger recovery.

Zacks | 1 month ago
Core Laboratories (CLB) Down 4.9% Since Last Earnings Report: Can It Rebound?

Core Laboratories (CLB) Down 4.9% Since Last Earnings Report: Can It Rebound?

Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 month ago
Implied Volatility Surging for Core Laboratories Stock Options

Implied Volatility Surging for Core Laboratories Stock Options

Investors need to pay close attention to CLB stock based on the movements in the options market lately.

Zacks | 1 month ago
Core Laboratories Q1 Earnings Meet Estimates, Decline Y/Y

Core Laboratories Q1 Earnings Meet Estimates, Decline Y/Y

CLB's Q1 earnings meet estimates but fall Y/Y as a revenue miss and Middle East disruptions weigh on both key segments.

Zacks | 2 months ago
Core Laboratories Inc. (CLB) Q1 2026 Earnings Call Transcript

Core Laboratories Inc. (CLB) Q1 2026 Earnings Call Transcript

Core Laboratories Inc. (CLB) Q1 2026 Earnings Call Transcript

Seekingalpha | 2 months ago
Core Laboratories to Post Q1 Earnings: Key Metrics to Watch

Core Laboratories to Post Q1 Earnings: Key Metrics to Watch

CLB heads into Q1 earnings with lowered guidance, geopolitical disruptions and cost pressures raising concerns over a potential earnings miss.

Zacks | 2 months ago
Earnings Preview: Core Laboratories (CLB) Q1 Earnings Expected to Decline

Earnings Preview: Core Laboratories (CLB) Q1 Earnings Expected to Decline

Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 2 months ago
Middle East Conflict Weighs On Core Laboratories' Q1 Outlook

Middle East Conflict Weighs On Core Laboratories' Q1 Outlook

CLB's operations remain disrupted amid geopolitical tensions, forcing a cut in Q1 2026 guidance due to supply chain issues and weaker client activity.

Zacks | 3 months ago
Here's Why Hold Strategy Is Apt for Core Laboratories Stock for Now

Here's Why Hold Strategy Is Apt for Core Laboratories Stock for Now

CLB is supported by offshore expansion, high-margin services and innovation, but pressured by geopolitical tensions, soft U.S. markets and oil price uncertainty.

Zacks | 3 months ago
Core Laboratories (NYSE:CLB) Shares Cross Above Two Hundred Day Moving Average   – Time to Sell?

Core Laboratories (NYSE:CLB) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?

Core Laboratories Inc. (NYSE: CLB - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $15.60 and traded as high as $16.29. Core Laboratories shares last traded at $15.8820, with a volume of 330,035 shares trading hands. Wall Street Analysts Forecast

Defenseworld | 4 months ago
Why Is Core Laboratories (CLB) Down 14.2% Since Last Earnings Report?

Why Is Core Laboratories (CLB) Down 14.2% Since Last Earnings Report?

Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?

Zacks | 4 months ago
Core Labs Jumps 79% in 6 Months: Time to Buy or Stay on the Sidelines?

Core Labs Jumps 79% in 6 Months: Time to Buy or Stay on the Sidelines?

CLB shows strong international demand, free cash flow generation and a solid financial position, but near-term U.S. land activity challenges and margin pressure could limit growth.

Zacks | 5 months ago
Loading...
Load More